ConductScience.org, home

Paper38948331

Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.

Christensen CL and 5 others. Mol Ther Nucleic Acids, 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells. Papers, record 38948331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38948331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.
PubMed
Journal
Mol Ther Nucleic Acids
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.93, provisional
iCite
Revised in PubMed
2025-07-20
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Christensen CLChloe L
2Kan SHShih-Hsin
3Andrade-Heckman PPerla
4Rha AKAllisandra K
5Harb JFJerry F
6Wang RYRaymond Y

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 AR079223NIAMS NIH HHSUnited StatesR01AR079223PubMed

Source NIH RePORTER

Download CSV of grants

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134079130Base editing of haematopoietic stem cells rescues sickle cell disease in mice.Nature2021https://conductscience.org/library/papers/34079130PubMed
232480002Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications.J Mol Diagn2020https://conductscience.org/library/papers/32480002PubMed
331392190Molecular genetics of Pompe disease: a comprehensive overview.Ann Transl Med2019https://conductscience.org/library/papers/31392190PubMed
433959386Muscle-Specific Promoters for Gene Therapy.Acta Naturae2021https://conductscience.org/library/papers/33959386PubMed
535119294Inference of CRISPR Edits from Sanger Trace Data.CRISPR J2022https://conductscience.org/library/papers/35119294PubMed
634737297Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates.Nat Commun2021https://conductscience.org/library/papers/34737297PubMed
726098369Engineered CRISPR-Cas9 nucleases with altered PAM specificities.Nature2015https://conductscience.org/library/papers/26098369PubMed
822930834NIH Image to ImageJ: 25 years of image analysis.Nat Methods2012https://conductscience.org/library/papers/22930834PubMed
933013846A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.Front Immunol2020https://conductscience.org/library/papers/33013846PubMed
1015585405Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.Mol Ther2005https://conductscience.org/library/papers/15585405PubMed
1134020684Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.Orphanet J Rare Dis2021https://conductscience.org/library/papers/34020684PubMed
1219775921Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.Mol Genet Metab2010https://conductscience.org/library/papers/19775921PubMed
1324463181Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases.Bioinformatics2014https://conductscience.org/library/papers/24463181PubMed
1423873081DNA targeting specificity of RNA-guided Cas9 nucleases.Nat Biotechnol2013https://conductscience.org/library/papers/23873081PubMed
1534850579Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity.EMBO Mol Med2022https://conductscience.org/library/papers/34850579PubMed
1636624150Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase.Nat Biotechnol2023https://conductscience.org/library/papers/36624150PubMed
1728814660Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.JCI Insight2017https://conductscience.org/library/papers/28814660PubMed
1829813047Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction.Nat Biotechnol2018https://conductscience.org/library/papers/29813047PubMed
1924715333Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.J Inherit Metab Dis2015https://conductscience.org/library/papers/24715333PubMed
2033116134Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants.Nat Commun2020https://conductscience.org/library/papers/33116134PubMed

See all 51 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42941997The Genetic Landscape of Pompe Disease in the Middle East, North Africa, and Turkey (MENAT Region): A Systematic Review of GAA Variants and Genotype-Phenotype Correlation.Int J Mol Sci2026https://conductscience.org/library/papers/42941997PubMed
41783848Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions.Front Neurol2026https://conductscience.org/library/papers/41783848PubMed
41345283Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders.Gene Ther2026https://conductscience.org/library/papers/41345283PubMed
39134822Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy.Mol Diagn Ther2024https://conductscience.org/library/papers/39134822PubMed
39100736Precision medicine in action for Pompe disease.Mol Ther Nucleic Acids2024https://conductscience.org/library/papers/39100736PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GAA2548PubTator's text mininghttps://conductscience.org/library/genes/2548NCBI Gene
LAMP23920PubTator's text mininghttps://conductscience.org/library/genes/3920NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38948331

GET https://conductscience.org/api/papers/v1/38948331/references?page=2